SOURCE: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc.

November 11, 2013 08:00 ET

Matinas BioPharma Appoints Jerome Jabbour as Chief Business Officer and General Counsel

Jabbour Bolsters Management Team With Significant Industry, Operational and Legal Expertise; Former Reliant Pharmaceuticals Executive Played Key Role in Commercial Operations Planning and Launch of First Prescription Omega-3 Product; Lovaza®/Omacor®

BEDMINSTER, NJ--(Marketwired - November 11, 2013) - Matinas BioPharma Holdings, Inc., an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular conditions, announced today the appointment Jerome D. Jabbour as Executive Vice President, Chief Business Officer and General Counsel. Mr. Jabbour is a co-Founder and current Board member of Matinas BioPharma. He brings to the Company over a decade of specialized experience in the biopharmaceutical industry, with expertise heading legal, intellectual property and commercial operations.

Mr. Jabbour joins Matinas BioPharma at an important time for the Company following the recent closing of its $15 million financing, which positioned the Company to begin advancing the development of its innovative omega-3 lead product candidate, MAT9001, for the treatment of severe hypertriglyceridemia and mixed dyslipidemia. He will play a key role in building upon the Company's intellectual property portfolio and spearheading all business and commercial operations relating to MAT9001.

Herbert Conrad, Matinas BioPharma's Chairman of the Board, commented, "In addition to being a co-Founder and Board member of Matinas BioPharma, Jerry is an excellent addition to this highly-experienced management team. His broad legal and operational experience, combined with his successful track record in the omega-3 space, is perfectly aligned with the Company's priorities."

Mr. Jabbour has extensive experience in the pharmaceutical and healthcare industries, both domestically and internationally. Prior to joining Matinas BioPharma, he served as Executive Vice President, General Counsel & Secretary of MediMedia, a diversified health care services company. Prior to MediMedia, he was the Senior Vice President and Head of Global Legal Affairs for Wockhardt Limited, a global pharmaceutical and biotechnology company with over $1 billion in global revenues at the time of his departure. During his time at Wockhardt, Mr. Jabbour played a significant business role in Wockhardt's sales in the U.S., which grew from less than $50 million in 2008 to more than $500 million during 2012. Immediately prior to that, he served as Commercial Counsel and Assistant Secretary at Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary, where he was directly involved with the in-licensing of Omacor®/Lovaza® and was subsequently responsible for all legal aspects related to clinical and supply chain development, as well as Reliant's intellectual property portfolio. Mr. Jabbour also played a key role in the strategic purchase of Reliant by GlaxoSmithKline in 2007 for $1.65 billion. Earlier in his career, he held positions as counsel at Alpharma and in private practice at Lowenstein Sandler LLP. Mr. Jabbour earned his J.D. from Seton Hall University School of Law in Newark, New Jersey and a B.A. from Loyola University in Baltimore, Maryland.

Roelof Rongen, Matinas BioPharma's Chief Executive Officer, stated, "I am very pleased to have Jerry join the Company's executive management team at such an important time. The next few years will prove to be a very exciting time for Matinas BioPharma. I firmly believe we have built an exceptional team that will be instrumental in the successful development of MAT9001 and ensuring this new omega-3 product candidate will secure a prominent place in this well established and growing market."

About MAT9001
Matinas BioPharma is developing MAT9001 for therapeutic applications, with severe hypertriglyceridemia (TG > 500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/d with concomitant statin therapy) as the lead indications. Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration and conduct a human study in the first half of 2014. Assuming positive data from this study, Matinas BioPharma anticipates commencing the first of its pivotal Phase 3 registration studies in 2014. The Company believes that the composition of MAT9001 represents a significantly differentiated lipid profile, providing unique clinical benefits.

About Matinas BioPharma
Matinas BioPharma Holdings, Inc. is an early stage privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of cardiovascular conditions. The Company's lead product candidate, MAT9001, is designed for treatment of severe hypertriglyceridemia (TG > 500 mg/dl) and mixed dyslipidemia (TG 200-499 mg/dl while on statin therapy). The Matinas BioPharma management team brings a cumulative multi-decade omega-3 pharmaceutical experience to the Company, providing a unique perspective and capability for the development of the next generation of omega-3-fatty acid-based pharmaceutical products.

For more information, please visit

Forward Looking Statements: This release contains "forward-looking statements", including those related to the Company's strategic focus and the future development MAT9001. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Investor and Media Contact
    Jenene Thomas
    Investor Relations and Corporate Communications Advisor
    Jenene Thomas Communications, LLC
    Phone: +1 (908) 938-1475